The company divested its API business in India in June 2024 and closed the OTC transaction in July 2024. These divestitures are part of the company's strategy to streamline operations and focus on core areas.

The company acquired development programs and personnel from Idorsia for $350 million upfront, plus potential milestone payments and royalties. This expands the company's portfolio with two Phase 3 assets.

On a constant currency basis, net sales from the remaining business increased by approximately 2%. New product sales, primarily in the U.S., of approximately $209.9 million helped offset base business erosion of approximately $125.4 million.

The company recorded a goodwill impairment charge of $321.0 million related to its JANZ reporting unit, indicating that management's expectations for this region have been revised downwards.

The company paid a quarterly dividend of $0.12 per share and continued its share repurchase program, demonstrating a commitment to returning capital to shareholders.

The company continues to execute its integration and restructuring plans, as evidenced by transaction-related costs and restructuring-related costs in the income statement.

The company is involved in various disputes, governmental and/or regulatory inquiries, investigations and proceedings, tax proceedings and litigation matters, both in the U.S. and abroad, that arise from time to time, some of which could result in losses.

The preliminary fair value estimates for the assets acquired and liabilities assumed were based upon preliminary calculations, valuations and assumptions that are subject to change as the Company obtains additional information during the measurement period

The Company has recorded a net reserve for uncertain tax positions of $239.3 million and $287.1 million, including interest and penalties, in connection with its international audits at June 30, 2024 and December 31, 2023, respectively. In connection with our international tax audits, it is possible that we will incur material losses above the amounts reserved.

The Company anticipates lower net sales of certain existing products within the U.S., including EpiPen® Auto-Injector and Perforomist®, as a result of lower pricing and volumes due to additional competition and unfavorable channel dynamics.

Beginning in February 2023, we brought patent infringement actions against the generic filers in federal district courts asserting infringement of the patents by the generic companies.

Sales continue to be negatively affected by the impact of tender systems in certain countries.

The Company has undertaken restructurings and other optimization initiatives of differing types, scope and amount during the covered periods and, therefore, these charges should not be considered non-recurring

Certain costs to further develop and optimize our global enterprise resource planning systems, operations and supply chain

The company divested its API business in India in June 2024 and closed the OTC transaction in July 2024. These divestitures are part of the company's strategy to streamline operations and focus on core areas.

R&D expense for the three months ended June 30, 2024 was $204.1 million, compared to $208.3 million for the comparable prior year period, a decrease of $4.2 million due to the timing of clinical development programs.

The company acquired development programs and personnel from Idorsia for $350 million upfront, plus potential milestone payments and royalties. This expands the company's portfolio with two Phase 3 assets.

Viatris provides access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris.

During the six months ended June 30, 2024 and 2023, the Company repurchased approximately 19.2 million shares of common stock at a cost of approximately $250 million, and approximately 21.2 million shares of common stock at a cost of approximately $250 million, respectively, under the program.

The Company paid a quarterly dividend of $0.12 per share on the Company's issued and outstanding common stock on March 18, 2024 and June 14, 2024.

While there can be no assurance that current expectations will be realized, capital expenditures for the 2024 calendar year are expected to be approximately $350 million to $450 million.

The 10-Q filing does not explicitly mention any specific ESG initiatives or targets.

The decrease in net sales was partially driven by the unfavorable impact of foreign currency translation of approximately $98.9 million, or 3%, primarily reflecting changes in the U.S. Dollar

Net sales from JANZ decreased by $25.9 million or 7% for the three months ended June 30, 2024 when compared to the prior year period. This decrease was the result of the unfavorable impact of foreign currency translation of approximately $29.9 million, or 8%. Constant currency net sales increased by approximately $4.5 million, or 1%, when compared to the prior year period, driven primarily by new product sales in Australia and volume growth of our promoted brands in Japan. This increase was partially offset by lower net sales of existing products mainly driven by lower pricing in Japan as a result of government price reductions and additional competition.

our results of operations, cash flows and financial condition could also be affected by other risks of doing business internationally, including the impact of inflation, elections, geopolitical events, including the ongoing conflicts in the Middle East and between Russia and Ukraine and related trade controls, sanctions, supply chain and staffing challenges and other economic considerations, supply chain disruptions, foreign currency exchange fluctuations, public health epidemics, changes in intellectual property legal protections and other regulatory changes.